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Carbapenem-resistant Klebsiella pneumoniae isolates producing K. pneumoniae carbapenemases (KPC) were first reported in the 
USA in 2001, and since then, this infection has been reported in Europe, Israel, South America, and China. In Korea, the first KPC-2-
producing K. pneumoniae sequence type (ST) 11 strain was detected in 2010. We report the case of a patient with a urinary tract in-
fection caused by KPC-2-producing K. pneumoniae. This is the second report of a KPC-2-producing K. pneumoniae infection in Ko-
rea, but the multilocus sequence type was ST258. The KPC-2-producing isolate was resistant to all tested β-lactams (including imi-
penem and meropenem), amikacin, tobramycin, ciprofloxacin, levofloxacin, and trimethoprim-sulfamethoxazole, but was suscep-
tible to gentamicin, colistin, polymyxin B, and tigecycline. The KPC-2-producing isolate was negative to phenotypic extended-spec-
trum β-lactamase (ESBL) and AmpC detection tests and positive to modified Hodge test and carbapenemase inhibition test with 
aminophenylboronic acid.
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INTRODUCTION
The resistance of Klebsiella pneumoniae to carbapenems is 
mainly associated with acquired carbapenemases [1]. These 
carbapenemases can be Ambler class A (KPC, GES), class B 
(VIM, IMP), and class D (OXA-48) enzymes [2]. The most 
common class A carbapenemases in K. pneumoniae are the 
K. pneumoniae carbapenemases (KPCs) [3]. KPC-produc-
ing K. pneumoniae strains were first reported in 2001 in the 
USA [4] and dissemination has been reported in Europe, 
Israel, South America, and China [5-9]. The first KPC-2-
producing K. pneumoniae strain in Korea was isolated from 
bronchial aspirates from a patient admitted to the intensive 
care unit (ICU) in 2010 [10]. KPC-producing K. pneumo­
niae also produce VIM or CTX-M, making it difficult to se-
lect appropriate antibiotics [11]. In addition, the mortality 
rate is significantly higher for patients with KPC-producing 
isolates than those with imipenem susceptible isolates [12]. 
In this report, we describe a case of infection with a KPC-2-
producing K. pneumoniae isolate, sequence type (ST) 258 in 
Korea and various phenotypic methods for screening and 
confirmation. 
CASE REPORT
A 70-year-old woman was admitted to the Plastic Surgery 
(PS) department on October 5, 2010, with a 24-h history of 
fever and dizziness. She had a known history of unstable 
angina and diabetes mellitus (2001). In November 2009, she 
was admitted to the PS department for a skin flap operation 
(February, 2010) to treat a third-degree burn to the sacral 
area. Two months ago, a sore, approximately 10×10 cm in 
size, developed at the sacral area and progressed to osteo-
myelitis in the sacral bone. She had no recent travel history 
abroad. At admission, she was pale and febrile with a tem-Roh KH, et al.  •  KPC-2-producing K. pneumoniae ST258
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perature of 38.2°C. An intermittent fever of 37.3-38.1°C 
last  ed until hospital day (HD) 5. Her blood pressure was 
110/80 mmHg, her pulse was 78/min, and her respiratory 
rate was 20/min. A laboratory investigation at the time of 
admission revealed a peripheral white blood cell (WBC) 
count of 8,730/μL (73.5% neutrophils), a hemoglobin level 
of 8.6 g/dL, and a platelet count of 261,000/μL. Routine 
blood chemistry results were AST/ALT of 7/11 U/L, alka-
line phosphatase of 77 U/L, blood urea nitrogen/creatinine 
of 23.4/1.42 mg/dL, and total protein/albumin of 5.6/2.9 g/
dL. Erythrocyte sedimentation rate and C-reactive protein 
were both increased to 53 mm/hr and 220.03 mg/L, respec-
tively. The urine was yellow and turbid and routine urinaly-
sis revealed a positive WBC (3+), and positive protein (1+). 
Microscopic examination of urine revealed >60 WBCs and 
yeast organisms in a high power field. A chest radiograph 
showed right pleural thickening and a little collapse of the 
right lower lung. An abdomen and pelvic computed tomog-
raphy showed signs of cystitis and fluid collection in both 
the abdomen and pleural cavity. 
Two sets of blood culture bottles and a urine sample were 
taken for microbiologic study. Aerobic and anaerobic blood 
cultures were all negative after 5 days of incubation. In the 
urine culture, Candida albicans (8×10
4 CFU/mL) grew on 
a blood agar plate. On HD 32, the patient had a fever of 
38.1°C. Two sets of blood culture bottles and a urine sample 
were collected again for culture study. The blood culture re-
sults were negative. Multidrug-resistant K. pneumoniae (KPN 
1010, >10
5 CFU/mL) was isolated from the urine. Vitek2 
GN and AST-N044 (bioMérieux, Marcy l’Étoile, France) 
were used for species identification and antimicrobial sus-
ceptibility test, respectively. With the exception of gentami-
Table 1. MICs (μg/mL) of the KPC-2-producing Klebsiella pneumoniae isolate
Antimicrobial agent Vitek2 E-test
Ampicillin ≥32 >256
Amoxicillin-clavulanate ≥32 >256
Piperacillin ≥128 >256
Piperacillin-tazobactam ≥128 >256
Cephalothin ≥64
Cefoxitin ≥64 >256
Cefotetan >256
Cefotaxime ≥64 >256
Ceftazidime ≥64
Aztreonam ≥64 >256
Cefepime ≥64 >256
Imipenem ≥16 >256
Meropenem ≥16 >256
Amikacin ≥64       48
Tobramycin ≥16
Gentamicin 4
Levofloxacin ≥8
Ciprofloxacin >32
Trimethoprim-sulfamethoxazole  ≥320
Tigecycline 1
Colistin 0.25
Polymyxin B 0.75
Abbreviations: MIC, minimum inhibitory concentration; KPC, K. pneumoniae carbap-
enemase.
Fig. 1. Results obtained with a Modified Hodge test (A) and carbapenemase inhibition test (B) for carbapenem-resistant Klebsiella pneumoniae isolate (KPN 1010). 
Abbreviations: MEM, meropenem; APB, aminophenylboronic acid; CLX, cloxacillin; EDTA, ethylenediaminetetraacetic acid; DPA, dipicolinic acid.
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cin, all susceptibility results showed high-level minimum 
inhibitory concentration (MIC) values. MICs were also as-
sessed by E-test (bioMérieux). Most antibiotics were resis-
tant and consistent with the MIC of Vitek2. However, MICs 300     www.kjlm.org
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of tigecycline and colistin were 1 and 0.25 μg/mL, respec-
tively (Table 1). The modified Hodge test [13] demonstrated 
strong positivity (Fig. 1A) but AmpC and ESBL phenotypic 
tests [14] were negative. Carbapenemase inhibition tests were 
performed for discrimination of carbapenemases. Briefly, 
meropenem disks (Becton-Dickinson, Cockeysville, MD, 
USA) were supplemented with 10 μL of 4 different β-lacta-
mase inhibitors: 60 mg/mL aminophenylboronic acid (APB; 
Sigma St. Louis, MO, USA), 75 mg/mL cloxacillin (Sigma), 
100 mg/mL dipicolinic acid (DPA; Sigma), and 0.2 M ethyl-
enediaminetetraacetic acid (EDTA; Sigma). A 0.5 McFar-
land inoculum was prepared and spread on Mueller-Hinton 
agar plates (Becton-Dickinson). Five disks were placed on 
each plate: meropenem, meropenem+APB, meropenem+ 
cloxacillin, meropenem+DPA, meropenem+EDTA. A pos-
itive response was achieved when there was a greater than 5 
mm increase of the inhibition zone diameter around disks 
containing β-lactamase inhibitors, as compared with the 
meropenem disk alone [15]. The positive result was seen 
only with APB (Fig. 1B). 
PCR and DNA sequencing were performed with primers 
specific for the blaVIM, blaIMP, blaSIM, blaNDM, and bla  KPC genes 
[16-18]. We found only the blaKPC-2 gene. Mul  tilocus sequen  ce 
typing (MLST) with 7 housekeeping genes (rpoB, gapA, mdh, 
pgi, phoE, infB, and tonB) was performed [19]. The MLST 
showed that the isolate belonged to the epidemic clone ST258. 
Initially, the patient was treated with ertapenem (1 g once a 
day). After multidrug-resistant (MDR) K. pneumoniae was 
isolated from urine and the sacral sore wound, tigecycline 
(50 mg twice a day) was administrated for 14 days. How-
ever, neither pyuria nor the wound subsided, and MDR K. 
pneumoniae was repeatedly isolated. Lastly, the patient was 
treated with colistin (150 mg once a day), but clinical im-
provement was not observed and kidney function was de-
clining. She was managed in ICU, but expired on the 90th 
HD due to septic shock and multiorgan failure.
DISCUSSION
The most common mechanism of carbapenem-resistant 
K. pneumoniae in Korea is ESBL and/or AmpC β-lactamase 
plus porin loss [20]. Only a single case of KPC-2-producing 
strain has been described in Korea and the MLST type was 
ST11 [10]. This isolate showed an MDR pattern to various 
antibiotics, including colistin. The previous patient was treat  ed 
with colistin, but the prognosis was also poor. This is the 
second report of a KPC-2-producing K. pneumoniae in Ko-
rea. The isolate was not associated with travel and the MLST 
type was ST258. ST258 accounts for 70% of KPC-producing 
K. pneumoniae in the USA [21]. Isolates of ST258 have also 
been identified in Europe and Israel, indicating an interna-
tional spread of ST258 among KPC-producing K. pneumo­
niae [6, 7].
Most KPC-producing K. pneumoniae have been associ-
ated with other β-lactamase genes, such as the widespread 
ESBL gene blaCTX-M [22]. The previous KPC-2-producing K. 
pneumoniae isolate in Korea also contained blaCTX-M-15 [10]. 
However, the KPN 1010 isolate contained neither ESBL nor 
AmpC gene in this study.
The KPN 1010 isolate was susceptible to gentamicin, co-
listin, polymyxin B, and tigecycline, but the previous Korean 
isolate was nonsusceptible to gentamicin, colistin, polymyxin 
B, and tigecycline [10].
A modified Hodge test accurately detects KPC, but is not 
able to discriminate from other carbapenemases [23]. A car-
bapenemase inhibition test, comprising a meropenem disk, 
and meropenem disks supplemented with APB (for detec-
tion of class A carbapenemases), cloxacillin (for detection 
of AmpC β-lactamases plus porin loss), DPA or EDTA (for 
detection of class B metallo-carbapenemases) accurately 
distinguishes between several different mechanisms medi-
ating reduced susceptibility to carbapenems in Enterobacte­
riaceae [15]. The isolate was positive to APB and negative to 
cloxacillin, DPA, and EDTA, suggesting a class A carbapen-
emase producing isolate.
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